<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315910</url>
  </required_header>
  <id_info>
    <org_study_id>17-500</org_study_id>
    <nct_id>NCT03315910</nct_id>
  </id_info>
  <brief_title>Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites</brief_title>
  <official_title>Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to help determine the most effective type or combination of treatments to offer
      patients seeking lung cancer screening who are smokers to help them reduce the number of
      cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the
      benefits of lung cancer screening by providing a blue print of best practices for screening
      sites to deliver tobacco treatment to their patients who are smokers, in a way that does not
      add burden to screening site staff and increases the chances of patients quitting smoking.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The investigators have chosen to conduct a full factorial experimental design.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who are tobacco abstinence</measure>
    <time_frame>6 months following study enrollment</time_frame>
    <description>biochemical verification of smoking abstinence will be conducted Consistent with Intent to Treat, unless self reported smoking abstinence is biochemically verified, (&lt;3 ng/ml for mailed salivary cotinine assay) for participants who fail to return the saliva sample, the cessation outcome will be considered non-abstinent.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1152</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Motivational Interviewing( MI) (Yes vs. No)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion &amp; Fulfillment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRT Lozenge (Yes vs. No)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion &amp; Fulfillment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Message Framing (Gain vs. Loss)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing (MI)</intervention_name>
    <description>two counseling sessions</description>
    <arm_group_label>Motivational Interviewing( MI) (Yes vs. No)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy (NRT)</intervention_name>
    <description>receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day</description>
    <arm_group_label>Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Lozenge</intervention_name>
    <description>6 packs of NRT 2mg lozenge</description>
    <arm_group_label>NRT Lozenge (Yes vs. No)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Message Framing</intervention_name>
    <description>health communication literature and quitting messages</description>
    <arm_group_label>Message Framing (Gain vs. Loss)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saliva sample</intervention_name>
    <description>saliva samples from those reporting abstinence and analyze samples</description>
    <arm_group_label>Message Framing (Gain vs. Loss)</arm_group_label>
    <arm_group_label>Motivational Interviewing( MI) (Yes vs. No)</arm_group_label>
    <arm_group_label>NRT Lozenge (Yes vs. No)</arm_group_label>
    <arm_group_label>Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Site Eligibility (as per SC self-report)

        &amp; Must be designated as an American College of Radiology (ACR) designated lung cancer
        screening site

          -  Reports at least one year of lung cancer screening experience

          -  Reports conducting at least 20 new initial screenings per month Site Coordinator (SC)
             Eligibility (as per SC self-report)

          -  Employed as a full-time Site Coordinator at participating lung cancer screening site
             Patient Eligibility (as per self-report)

          -  Between the ages of 55-80 years old

          -  Seeking baseline or annual follow-up LDCT lung cancer screening

          -  Have at least a 30 pack-year history of smoking

          -  Currently a smoker, defined as self-reported cigarette smoking (some days, every day)
             within the past 30 days.

          -  Must be reachable by telephone

          -  Must be English speaking due to the study materials being available in English only
             and limited available resources for translation.

        Exclusion Criteria:

        Patient (as per self-report)

          -  NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks
             or, unstable/worsening angina).

          -  Smokers who are receiving other tobacco treatment services or have used cessation
             medications (NRT, bupropion, varenicline) within the past month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Ostroff, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Ostroff, PhD</last_name>
    <phone>646-888-0041</phone>
    <email>ostroffj@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuelin Li, PhD</last_name>
    <phone>646-888-0047</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lee, MD</last_name>
      <phone>323-442-8721</phone>
    </contact>
    <investigator>
      <last_name>Christopher Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Muir Health</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Straznicka, MD</last_name>
      <phone>925-932-6330</phone>
    </contact>
    <investigator>
      <last_name>Michaela Straznicka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellStar Health System</name>
      <address>
        <city>LaGrange</city>
        <state>Georgia</state>
        <zip>30240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salman Fidahussein, MD</last_name>
      <phone>706-880-7222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Karush, DO</last_name>
      <phone>312-738-3732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riverside Healthcare</name>
      <address>
        <city>Kankakee</city>
        <state>Illinois</state>
        <zip>60901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Belford, MD</last_name>
      <phone>815-937-1237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center, Community Healthcare System</name>
      <address>
        <city>Crown Point</city>
        <state>Indiana</state>
        <zip>46307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Tothy, MD</last_name>
      <phone>219-310-2550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center Cancer Institute</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Hochhesier, MD</last_name>
      <phone>207-396-7760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Schneider, MD</last_name>
      <phone>516-663-9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ostroff, PhD</last_name>
      <phone>646-888-0041</phone>
    </contact>
    <contact_backup>
      <last_name>Yuelin Li, PhD</last_name>
      <phone>646-888-0047</phone>
    </contact_backup>
    <investigator>
      <last_name>Jamie Ostroff, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Pua, MD</last_name>
      <phone>212-746-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System Blue Ridge</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Davidson, MD</last_name>
      <phone>828-580-4577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarrod T Bruce, MD</last_name>
      <phone>740-689-6833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Fein, MD</last_name>
      <phone>503-413-5702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Erkmen, MD</last_name>
      <phone>215-707-9115</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco Treatment</keyword>
  <keyword>Lung CT</keyword>
  <keyword>Cancer Screening</keyword>
  <keyword>17-500</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

